Olema Pharmaceuticals, Inc. (OLMA) Research
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Market snapshot
- Symbol
- OLMA
- Price
- $9.51
- Day change
- +0.74%
- Market cap
- $830.7M
- P/E ratio
- -5.28x
- 52-week range
- 4.02-36.259
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $41.20
Peer companies
Recent insider activity
- Raman Prakash — A-Award (24150 shares) on 2026-04-28
- Raman Prakash — A-Award (2911 shares) on 2026-04-28
- Raman Prakash — trade (0 shares) on 2026-04-28
- Mitchell Shawnte — M-Exempt (15000 shares) on 2026-03-03
- Mitchell Shawnte — M-Exempt (25000 shares) on 2026-03-04
Open Olema Pharmaceuticals, Inc. (OLMA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.